DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20175234

Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone

Avinash P. Dubbewar, B. Pathak, Manas Biswas, Gunjan Malhotra

Abstract


Background: Ovarian cancers are diagnosed at an advanced stage. Early diagnosis is the key to reduce death from ovarian cancer. The present study is an effort to assess the suitability of combined test using CA 125 and Inhibin for early diagnosis of ovarian cancer as compared to CA125 or Inhibin alone.

Methods: Fifty women with clinical suspicion of ovarian malignancy attending Gynae OPD were enrolled. All of these women were subjected to estimation of CA 125 and Inhibin levels prior to surgical intervention. A value of 35 IU/ml was taken as positive for CA 125. For Inhibin, 10.5 pg/ml was taken as cut off for premenopausal patients, whereas, any detectable assays were taken as positive for postmenopausal patients. The results were analyzed after establishing final histopathology of the disease.

Results: Out of 50 patients recruited, 30 (60%) were found to have carcinoma ovary and 20 (40%) were found to have benign diseases. Out of 30 cases of carcinoma ovary, CA125 was raised in 81% of cases and Inhibin was raised in 78% of cases. For detection of carcinoma ovary, CA 125 was found to have a sensitivity of 90% and specificity of 60% with a positive predictive value of 77% and negative predictive value of 80% which were statistically significant. Sensitivity and specificity of serum Inhibin for the same was 86.6% and 20% respectively. The positive and negative predictive value were 61.9% and 50%, which were not statistically significant. Sensitivity and specificity of combined CA125 and Inhibin were 100% and 30% respectively. The positive and negative predictive value were 68.1% and 100% respectively, which were statistically significant.

Conclusions: Combined use of CA125 and Inhibin has got better sensitivity and specificity in detection of ovarian cancer in comparison to CA 125 or Inhibin used alone. 


Keywords


CA 125, Epithelial, Inhibin, Mucinous, Ovarian, Serous

Full Text:

PDF

References


Bast RC, Klug TL, St John E. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-7.

Montag TW. Tumor markers in gynecologic oncology. Obstet Gynecol Surv. 1990;45:94-105.

Lappohn RE, Burger HG, Bouma J, Bangah M, Krans M, de Bruijn HWA. Inhibin as a marker for granulosa-cell tumors. N Engl J Med. 1989;321:790-3.

Robertson DM, Pruysers E, Burger HG, Jobling T, McNeilage J, Healy D. Inhibin and ovarian cancer. Molecular Cellular Endocrinol. 2004;225(2004):65-71.

Lappohn RE, Burger HG, Bouma J, Bangah M, Krans M, de Bruijn HWA. Inhibin as a marker for granulosa-cell tumors. N Engl J Med. 1989;321:790-3.

Jacobs I, Davies AP, Bridges J. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br Med J. 1993;306(6884):1030-4.

Zurawski VR, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC, et al. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol. 1990;36(3):299-305.

Vora, Bhargava VL. Clinicopathological study of ovarian neoplasms. J Obst Gynae India. 1969;19:358.

Reddy JN, Rao S, Shrinivas. Incidence of ovarian tumour. J Obst Gynae India. 1971;21:727.

Ramachandran G, Hiralal KR, Chinnama KK. Ovarian neoplasms. J Obst Gynae India. 1971;29:309.

Schuter EMJ, Davelar EM, Van Kamp GJ. The differential diagnostic potential of a panel of tumour markers in patient with pelvic masses. Am J Obstet Gynaecol. 2002;187(2):385-92.

Stakes SJ, Menon U, Donald MN. Calculation of the risk of ovarian cancer from serial CA 125 level for pre-clinical detection in postmenopausal women. J Clin Oncol. 2003;15:2065-103.

Buys SS, Partridge E, Greene MH. PCLO Project team. Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynaecol. 2005;193:1630-9.

Jobling T, Mamers P, Healy DL, McLachlan V, Burger HG, Quinn M, et al. A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol. 1994;55:285-9.

Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumours. N Eng J Med. 1993;329:1539-42.

Robertson DM, Pruysers E, Jobling T. Inhibin as a diagnostic marker for ovarian cancer. Cancer Letters. 2007;249(1):14-7.